{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:09:25Z","timestamp":1787832565704,"version":"build-2784847793"},"reference-count":87,"publisher":"Informa UK Limited","issue":"20","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Adaptimmune"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.2217\/fon-2020-1092","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T09:25:11Z","timestamp":1618997111000},"page":"2659-2670","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacotherapy for Liposarcoma: Current and Emerging Synthetic Treatments"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-1341","authenticated-orcid":false,"given":"Florence","family":"Chamberlain","sequence":"first","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust,\rLondon, SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3241-3630","authenticated-orcid":false,"given":"Charlotte","family":"Benson","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust,\rLondon, SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin","family":"Thway","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust,\rLondon, SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3972-5087","authenticated-orcid":false,"given":"Paul","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research,\rLondon, SW7 3RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-3844","authenticated-orcid":false,"given":"Robin L","family":"Jones","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust,\rLondon, SW3 6JJ, UK"},{"name":"Institute of Cancer Research,\rLondon, SW7 3RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-7696","authenticated-orcid":false,"given":"Spyridon","family":"Gennatas","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust,\rLondon, SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9598"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020294"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22239"},{"key":"e_1_3_2_6_1","unstructured":"Cancer Research UK . Soft tissue sarcoma incidence statistics. (2010). (Accessed 2April2019) www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/soft-tissue-sarcoma\/incidence#heading-Zero"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.07.023"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21605"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr485"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4996"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0584"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12132-w"},{"key":"e_1_3_2_13_1","first-page":"8928706","article-title":"Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution","volume":"2018","author":"Muratori F","year":"2018","unstructured":"Muratori F , BettiniL, FrenosFet al. Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution. Int. J. Surg. Oncol.2018, 8928706 (2018).","journal-title":"Int. J. Surg. Oncol."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24375"},{"key":"e_1_3_2_15_1","first-page":"483154","article-title":"Liposarcoma: molecular genetics and therapeutics","volume":"2011","author":"Thomas DM","year":"2011","unstructured":"Thomas DM , ConyersR, YoungS. Liposarcoma: molecular genetics and therapeutics. Sarcoma2011, 483154 (2011).","journal-title":"Sarcoma"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.619"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds219"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-016-0060-4"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy052"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30446-0"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158406"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000086542.11899.38"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1315173"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3739159"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-4-16"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70175-4"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70031-8"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr265"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30334-0"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S93517"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6605"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Chen TW-W YuC-W HongR-Let al. A Ib\/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER). (2020). https:\/\/meetinglibrary.asco.org\/record\/185573\/abstract","DOI":"10.1200\/JCO.2020.38.15_suppl.11507"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00408-7"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11290"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32084"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6107"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3223"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30926"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.11039"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11506"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29961"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11550"},{"key":"e_1_3_2_49_1","unstructured":"Gemcitabine hydrochloride with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. (2012). (Accessed 2April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01532687"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_3"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30507-1"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25843"},{"key":"e_1_3_2_54_1","unstructured":"Sitravatinib in advanced liposarcoma and other soft tissue sarcomas. (2016). (Accessed 3April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02978859"},{"key":"e_1_3_2_55_1","unstructured":"Ph II nintedanib vs. ifosfamide in soft tissue sarcoma (ANITA). (2016). (Accessed 9April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808247"},{"key":"e_1_3_2_56_1","unstructured":"A study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas (Axi-STS). (2010). (Accessed 12September2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01140737"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"e_1_3_2_59_1","unstructured":"Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression (PalboSarc). (2017). (Accessed 2April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03242382"},{"key":"e_1_3_2_60_1","unstructured":"A study assessing efficacy & safety of ribociclib in patients with advanced well\/dedifferentiated liposarcoma. (2017). (Accessed 2April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03096912"},{"key":"e_1_3_2_61_1","unstructured":"Study of abemaciclib in dedifferentiated liposarcoma. (2016). (Accessed 2April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02846987"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.2581"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11514"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0482-3"},{"key":"e_1_3_2_66_1","unstructured":"Sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma. (2016). (Accessed 3April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02821507"},{"key":"e_1_3_2_67_1","unstructured":"Phase II trial of ribociclib and everolimus in advanced dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS). (2017). (Accessed 3April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03114527"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.10005"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6346"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11512"},{"key":"e_1_3_2_72_1","volume-title":"CTOS 2020 Virtual Annual Meeting.","author":"Grounder M","year":"2020","unstructured":"Grounder M , AbdulRazak A, SomaiahNet al. A Phase 2\/3, randomized, double blind, cross-over, study of selinexor versus placebo in advanced unresectable dedifferentiated liposarcoma (DDLS). Presented at: CTOS 2020 Virtual Annual Meeting. (18\u201321 November 2020)."},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601306"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3951"},{"issue":"9","key":"e_1_3_2_75_1","first-page":"5133","article-title":"Phase I study of efatutazone, an oral PPAR\u03b3 agonist, in patients with metastatic solid tumors","volume":"34","author":"Murakami H","year":"2014","unstructured":"Murakami H , OnoA, TakahashiTet al. Phase I study of efatutazone, an oral PPAR\u03b3 agonist, in patients with metastatic solid tumors. Anticancer Res.34(9), 5133\u20135141 (2014).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_76_1","unstructured":"Efatutazone dihydrochloride in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery. (2014). (Accessed 3April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02249949"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1068"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.008"},{"key":"e_1_3_2_79_1","unstructured":"Ph II cabazitaxel DD liposarcoma. (2013). (Accessed 2April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01913652"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11015"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4829-0"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1419068"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.133"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27446"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw281"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e23570"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6329"},{"key":"e_1_3_2_89_1","unstructured":"Lenvatinib and eribulin in advanced soft tissue sarcoma (LEADER). (2018). (Accessed 3April2019) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03526679"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:08Z","timestamp":1719125228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":87,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.2217\/fon-2020-1092"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1092","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}